EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prenatal Screening for CMV Primary Infection: A Cost‐Utility Model

Gebrael El Hachem, Thomas G Poder, Catherine McCarey, Soren Gantt, Fatima Kakkar, Marc Sab, Christian Renaud, Isabelle Boucoiran iD

BJOG: An International Journal of Obstetrics & Gynaecology · 2025

DOI: 10.1111/1471-0528.18080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJOG: An International Journal of Obstetrics & Gynaecology, 2025. Verfasst von Gebrael El Hachem und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Université de Montréal, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Pregnancy Complications, Infectious, Prenatal Diagnosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Réseau Mère-Enfant de la Francophonie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Congenital cytomegalovirus (CMV) infection is a major cause of deafness and neurodevelopmental disability in children. Our objective was to assess the cost utility of first‐trimester serological CMV screening, compared to screening of high‐risk pregnancies and no serological screening.

Design

A decision‐analytic model was created to compare the cost utility of three strategies from a healthcare sector perspective: universal first‐trimester serological screening, screening only of high‐risk pregnant women (both including antiviral prophylaxis in cases of primary infection) and serological testing triggered by foetal morphological ultrasound (no CMV serological screening).

Setting

Canada. Population Hypothetical population of 80 000 pregnant women.

Methods

Probability, expected values and cost estimates were derived from published literature and local hospital and national insurance data. Main Outcome Measure Cost per maternal and infant quality‐adjusted life year (QALY) lost.

Results

Universal serological screening was superior to both screening of high‐risk women and no screening (utility of −0.42, −0.63 and − 0.87 QALY lost, respectively). Sensitivity analysis demonstrated that universal screening was the most cost‐effective strategy regardless of the incidence of primary infection, the acceptability of amniocentesis and the efficacy of antiviral prophylaxis. In the Monte Carlo analyses, universal serological screening was the most cost‐effective option in 96.36% of simulations. Universal serological screening would allow detection of 152 cases of primary maternal CMV infection and would prevent 29 cases of congenital CMV infection annually.

Conclusion

Our findings support the adoption of a population‐based prenatal screening programme for the prevention of congenital CMV infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsPregnancy Complications, InfectiousPrenatal DiagnosisHumansFemalePregnancyCost-Benefit AnalysisQuality-Adjusted Life YearsCanadaPregnancy Trimester, FirstAntiviral AgentsInfectious Disease Transmission, VerticalInfant, Newborn

Stichwörter der Autor:innen

cost utilitycytomegalovirusprenatal screening

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • School of Public Health, Université de Montréal, Montreal, Quebec, Canada.
  • Women and Children's Infectious Diseases Center, CHU Sainte-Justine Research Center, Montreal, Canada.
  • Research Center of the IUSMM, CIUSSS de l'Est de l'Île de Montréal, Montreal, Canada.
  • Department of Obstetrics and Gynecology, Université de Montréal, Montreal, Canada.
  • Department of Pediatrics, Université de Montréal, Montreal, Canada.
  • Faculty of Medicine, Université Catholique de Louvain, Brussels, Belgium.

ORCID-Profile: Isabelle Boucoiran

Förderung

  • Réseau Mère-Enfant de la Francophonie

Zitieren

APA

El Hachem, G., Poder, T. G., McCarey, C., Gantt, S., Kakkar, F., Sab, M., Renaud, C., & Boucoiran, I. (2025). Prenatal Screening for CMV Primary Infection: A Cost‐Utility Model. BJOG: An International Journal of Obstetrics & Gynaecology. https://doi.org/10.1111/1471-0528.18080

Vancouver

El Hachem G, Poder TG, McCarey C, Gantt S, Kakkar F, Sab M, et al. Prenatal Screening for CMV Primary Infection: A Cost‐Utility Model. BJOG: An International Journal of Obstetrics & Gynaecology. 2025. doi:10.1111/1471-0528.18080

BibTeX
@article{ElHachem2025,
  author = {El Hachem, Gebrael and Poder, Thomas G and McCarey, Catherine and Gantt, Soren and Kakkar, Fatima and Sab, Marc and Renaud, Christian and Boucoiran, Isabelle},
  title = {Prenatal Screening for CMV Primary Infection: A Cost‐Utility Model},
  journal = {BJOG: An International Journal of Obstetrics & Gynaecology},
  year = {2025},
  doi = {10.1111/1471-0528.18080}
}
Kostenlos starten →